MaxCyte

Gaithersburg, MD
Platform Provider
CAR-T Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
62.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP

Quick Facts: MaxCyte

Signal Score
62.0/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Gaithersburg, MD
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About MaxCyte

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 63.0
M&A activity detected (1 articles)
Active fundraising/financial news (6 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
M&A activity detected (1 articles)
Active fundraising/financial news (6 articles)
Capacity 61.0
Regulatory milestones (2 articles)
Sites: Gaithersburg, MD
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press20 articles
Regulatory milestones (2 articles)

Recent News 20 articles

general 2026-04-27
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Volume Signals - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Market Hype Signals  Newser
Source →
general 2026-04-27
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Trade Ideas - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Community Trade Ideas  Newser
Source →
general 2026-04-27
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Delta Trends - Newser
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27 - Delta Trends  Newser
Source →
general 2026-04-22
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Cổng thông tin điện tử Tỉnh Sơn La
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.  Cổng thông tin điện tử Tỉnh Sơn La
Source →
general 2026-04-22
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - UBND thành phố Hải Phòng
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.  UBND thành phố Hải Phòng
Source →
general 2026-04-22
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Xã Vĩnh Công
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.  Xã Vĩnh Công
Source →
general 2026-04-22
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations. - Xã Thanh Hà
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.  Xã Thanh Hà
Source →
financial 2026-04-15
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline. - Dividend Safety - Newser
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline. - Expert Verified Trades  Newser
Source →
general 2026-04-06
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Early Entry - UBND thành phố Hải Phòng
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31% - Early Entry  UBND thành phố Hải Phòng
Source →
regulatory 2026-03-26
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection - Bitget
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection  Bitget
Source →
general 2026-03-26
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development  Minichart
Source →
regulatory 2026-03-26
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection - Bitget
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection  Exchange Bitget
Source →
financial 2026-03-25
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1  Minichart
Source →
general 2026-03-25
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside  Stock Titan
Source →
financial 2026-03-25
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - The Globe and Mail
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook  The Globe and Mail
Source →
financial 2026-03-24
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript  The Globe and Mail
Source →
financial 2026-03-24
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - AOL.com
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript  AOL.com
Source →
financial 2026-03-24
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Q4 Earnings Call Highlights  MarketBeat
Source →
general 2026-03-23
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO - Stock Titan
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO  Stock Titan
Source →
general 2026-03-23
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - The Manila Times
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer  The Manila Times
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.8
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy